RecruitingPhase 3NCT06357533
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Sponsor: AstraZeneca
Fort Worth, TX · Houston, TX · +60 more sites